Fig. 2From: Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 monthsMedian MIDAS score at baseline (y-axis) and up to 30 months of follow-up (x-axis). Ninety-five percent confidence interval of median shown by vertical barsBack to article page